oxidative degradation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-19 and is reviewed periodically as new material appears.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Includes two non-natural residues |
| Molecular weight | About 711.9 g/mol | Confirmed by mass spectrometry |
| Appearance | White to off-white powder | Typical lyophilized form |
| Receptor target | GHS-R1a | Ghrelin receptor agonist |
| Plasma half-life | Roughly 2 hours | Varies by species and assay |
Lyophilized material is generally stored cold and dry, with desiccant, and protected from light. In solution the peptide is more vulnerable: the histidine side chain can oxidize, and repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. A mildly acidic aqueous buffer is often used for short-term handling because it limits several degradation routes. Accurate prediction of long-term stability under a given set of conditions is difficult, and published stability data remain sparse.
Published discussion of this compound is uneven. Some references describe it as a tool for probing growth hormone regulation, while others focus on analytical characterization or on comparisons with related secretagogues. Statements about selectivity, half-life and potency often trace back to a small number of original reports that later authors cite secondhand. Readers evaluating a claim should therefore check whether a figure reflects a direct measurement or a repeated citation, and whether the underlying study was conducted in animals, in isolated cells or in human volunteers.
Identity and purity assessment for a research peptide of this kind typically combines reversed-phase high-performance liquid chromatography with mass spectrometry. The chromatographic run separates related impurities and yields a purity percentage, while electrospray ionization or matrix-assisted laser desorption mass spectrometry confirms the expected molecular mass. Amino acid analysis or tandem mass spectrometry sequencing can add confidence when material is intended for quantitative work. Laboratories differ in how they calculate and report purity, so figures from different sources are not always directly comparable.
Verification of identity and purity relies on analytical methods used across peptide chemistry. Reverse-phase high-performance liquid chromatography separates components by hydrophobicity and provides a purity estimate. Mass spectrometry confirms molecular mass and helps detect modifications. Together these techniques give complementary information about whether a sample matches its expected structure. Results depend on method parameters and reference standards, so reported purity values are meaningful only when the analytical conditions are stated. Consistency between laboratories requires comparable protocols and well-characterized reference materials.
Peptides such as ipamorelin are subject to chemical and physical degradation. Hydrolysis of peptide bonds, oxidation of susceptible residues, and aggregation are common pathways that reduce purity over time. The rate of these processes depends on temperature, moisture, pH, and the number of freeze-thaw cycles a sample undergoes. Because the compound is typically handled as a lyophilized powder, controlling moisture during storage is a central concern. Degradation products can be detected with separation techniques that resolve the parent peptide from related impurities.
Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.
Purity is normally reported as a percentage of total peak area, a figure that does not account for water content, residual solvents, or counterions. Trifluoroacetate and acetate are the most frequent counterions in lyophilized peptides, and they shift the true peptide content away from the mass of the powder. A separate quantitative assay is therefore needed to state content accurately. Certificates of analysis often omit these details, which makes batch-to-batch comparison difficult and limits conclusions drawn when results from different suppliers are compared.
Lyophilized material is generally held at minus twenty degrees Celsius or lower, protected from moisture and light. Repeated excursions to room temperature cause condensation inside the vial and gradual moisture uptake, both of which shorten shelf life. Containers should be allowed to equilibrate before opening so that water does not condense on the solid. Dividing a batch into single-use aliquots reduces freeze-thaw cycling. Solid peptide handled this way is usually considered stable for months to years, while the same material in solution degrades on a much shorter timescale.
== Production == Cyanocobalamin is commercially prepared by bacterial fermentation. Fermentation by a variety of microorganisms yields a mixture of methylcobalamin, hydroxocobalamin and adenosylcobalamin. These compounds are converted to cyanocobalamin by addition of potassium cyanide in the presence of sodium nitrite and heat. Since multiple species of Propionibacterium produce no exotoxins or endotoxins and have been granted GRAS status (generally regarded as safe) by the United States Food and Drug Administration, they are the preferred bacterial fermentation organisms for vitamin B12 production. Historically, the physiological form was initially thought to be cyanocobalamin. This was because hydroxocobalamin produced by bacteria was changed to cyanocobalamin during purification in activated charcoal columns after separation from the bacterial cultures (because cyanide is naturally present in activated charcoal). Cyanocobalamin is the form in most pharmaceutical preparations because adding cyanide stabilizes the molecule. The total world production of vitamin B12, by four companies (the French Sanofi-Aventis and three Chinese companies) in 2008 was 35 tonnes.
Brother Zachariah — formerly known as James "Jem" Carstairs, a Silent Brother, and the former parabatai of Will Herondale, who acts as a kind of uncle to James, Lucie and the others. He is also a first cousin to Cordelia and Alastair. Barbara Lightwood — The eldest child of Gideon Lightwood and Sophie Collins. Growing up, Barbara had the perfect Sight, the ability to see past glamours. She has an understanding with Oliver Hayward, whose family runs the York Institute. Barbara was very affectionate and protective over Thomas—to the point where he found it smothering—and was often considered more gentle than her sister. She was somewhat of a romantic, and wanted to become a dutiful wife rather than a strong Shadowhunter. During a demon attack in Regents Park, Barbara was bitten and collapsed. In her final moments, she was delirious and lashed out, clawing at Oliver who had been crying by her bedside. This unknowingly spread the infection to Oliver who fell ill and died shortly after. Thomas and the others dedicated themselves to not only making a cure but finding and putting an end to the demon attacks in her name. Eugenia Lightwood — The second child of Gideon Lightwood and Sophie Collins. Like Barbara, Eugenia was very affectionate and protective over Thomas, to the point where he found it smothering, and wants to become a dutiful wife rather than a strong Shadowhunter. She is considered stubborn and rebellious. Eugenia was seemingly dubbed "ruined" as she had apparently been found alone with a gentleman whom did not later propose to her.
== Research and development == Generate's research is centered on leveraging machine learning to program proteins for specific functions. Its platform is trained on extensive datasets comprising 160,000 protein structures and 190 million genetic sequences. This system identifies patterns linking protein sequence, structure, and function, which are then used to design new therapeutic proteins. The company's technology includes two core components: de novo protein generation, which allows for the creation of proteins without relying on existing biological templates, and an optimization suite to refine these proteins for therapeutic use. This approach addresses challenges like affinity, immunogenicity, and manufacturability. Generate has applied its platform across various modalities, including antibodies, peptides, enzymes, and antibody-drug conjugates (ADCs). Notable research outputs include antibodies targeting SARS-CoV-2 and preclinical assets in oncology, developed in collaboration with institutions like MD Anderson Cancer Center. To support its experimental work, Generate has invested in advanced facilities, such as a cryogenic electron microscopy (cryoEM) laboratory in Andover, Massachusetts. This lab enables the collection of high-resolution protein interaction data to further train its computational models. Generate's pipeline includes clinical and preclinical candidates addressing conditions like severe asthma and non-small cell lung cancer.
Sources: en.wikipedia.org
In cellular migration, an integral aspect of inflammatory responses, the inhibition of GSK-3 has been reported to play conflicting roles, as local inhibition at growth cones has been shown to promote motility while global inhibition of cellular GSK-3 has been shown to inhibit cell spreading and migration. GSK-3 is also integrally tied to pathways of cell proliferation and apoptosis. GSK-3 has been shown to phosphorylate Beta-catenin, thus targeting it for degradation. GSK-3 is therefore a part of the canonical Beta-catenin/Wnt pathway, which signals the cell to divide and proliferate. GSK-3 phosphorylates cyclins D and E, which are important for the transition from G1 to S phase, and causes their degradation. The transcription factors c-myc and c-fos (also S phase promoters ), which are primarily phosphorylated by the dual-specificity tyrosine phosphorylation-regulated kinase, are also phosphorylated by GSK3, causing them to be degraded. GSK-3 also participates in a number of apoptotic signaling pathways by phosphorylating transcription factors that regulate apoptosis. GSK-3 can promote apoptosis by both activating pro-apoptotic factors such as p53 and inactivating survival-promoting factors through phosphorylation. The role of GSK-3 in regulating apoptosis is controversial, however, as some studies have shown that GSK-3β knockout mice are overly sensitized to apoptosis and die in the embryonic stage, while others have shown that overexpression of GSK-3 can induce apoptosis.
Within months of the collapse of the Third Coalition, the Fourth Coalition (1806–1807) against France was formed by Britain, Prussia, Russia, Saxony, and Sweden. In July 1806, Napoleon formed the Confederation of the Rhine out of the many small German states which constituted the Rhineland and most other western parts of Germany. He amalgamated many of the smaller states into larger electorates, duchies, and kingdoms to make the governance of non-Prussian Germany smoother. Napoleon elevated the rulers of the two largest Confederation states, Saxony and Bavaria, to the status of kings. In August 1806, the Prussian king, Frederick William III, decided to go to war independently of any other great power. The army of Russia, a Prussian ally, in particular, was too far away to assist. On 8 October 1806, Napoleon unleashed all the French forces east of the Rhine into Prussia. Napoleon defeated a Prussian army at Jena (14 October 1806), and Davout defeated another at Auerstädt on the same day. 160,000 French soldiers (increasing in number as the campaign went on) attacked Prussia, moving with such speed that they destroyed the entire Prussian Army as an effective military force. Out of 250,000 troops, the Prussians sustained 25,000 casualties, lost a further 150,000 as prisoners, 4,000 artillery pieces, and over 100,000 muskets. At Jena, Napoleon had fought only a detachment of the Prussian force. The battle at Auerstädt involved a single French corps defeating the bulk of the Prussian army. Napoleon entered Berlin on 27 October 1806.
Mushrooms are used extensively in cooking, in many cuisines (notably Chinese, Korean, European, and Japanese). Humans have valued them as food since antiquity. Most mushrooms sold in supermarkets have been commercially grown on mushroom farms. The most common of these, Agaricus bisporus, is considered safe for most people to eat because it is grown in controlled, sterilized environments. Several varieties of A. bisporus are grown commercially, including whites, crimini, and portobello. Other cultivated species available at many grocers include Hericium erinaceus, shiitake, maitake (hen-of-the-woods), Pleurotus, and enoki. In recent years, increasing affluence in developing countries has led to a considerable growth in interest in mushroom cultivation, which is now seen as a potentially important economic activity for small farmers. China is a major edible mushroom producer. The country produces about half of all cultivated mushrooms, and around 2.7 kilograms (6.0 lb) of mushrooms are consumed per person per year by 1.4 billion people. In 2014, Poland was the world's largest mushroom exporter, reporting an estimated 194,000 tonnes (191,000 long tons; 214,000 short tons) annually. Separating edible from poisonous species requires meticulous attention to detail; there is no single trait by which all toxic mushrooms can be identified, nor one by which all edible mushrooms can be identified. People who collect mushrooms for consumption are known as mycophagists, and the act of collecting them for such is known as mushroom hunting, or simply "mushrooming".
John Calvin Giddings (September 26, 1930 – October 24, 1996) was a Distinguished Professor of chemistry at the University of Utah. Giddings received a B.S. degree from Brigham Young University in 1952 and a PhD from the University of Utah in 1954. Following postdoctoral work at the University of Utah and the University of Wisconsin, he joined the faculty of the University of Utah as assistant professor of chemistry in 1957. He became associate professor in 1959, research professor in 1962, and professor in 1966. Giddings authored or co-authored more than 400 publications and edited 32 books in the field of chemistry. He was executive editor of the journal Separation Science and Technology, and the editor of the series Advances in chromatography. Gidding's work in separation sciences shed light on the chromatographic processes, as well as other separation techniques, including non-equilibrium, diffusion & eddy diffusion, pressure changes, flow in paper and thin-layer chromatography, preparative-scale, and programmed-temperature gas chromatography (GC), exclusion chromatography, electrophoresis, and the generation of non-gaussian zones. He developed understanding of the optimization of multicomponent chromatography especially in 2D separations. His vision of the capabilities of high-pressure chromatographic systems evolved into High Performance Liquid Chromatography (HPLC), by suggesting to reduce particle size of the columns' packing in liquid chromatography.
Sources: en.wikipedia.org
=== Availability === Ketoconazole is available widely throughout the world. In 2013, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended that a ban be imposed on the use of oral ketoconazole for systemic use in humans throughout the European Union, after concluding that the risk of serious liver injury from systemic ketoconazole outweighs its benefits.
=== Not radioactive === Irradiated food does not become radioactive; only particle energies that are incapable of causing significant induced radioactivity are used for food irradiation. In the United States this limit is 4 mega electron volts (MEV) for electron beams and x-ray sources—cobalt-60 or caesium-137 sources are never energetic enough to induce radioactivity. Particles below this energy can never be energetic enough to modify the nucleus of the targeted atom in the food, regardless of how many particles hit the target material, and so radioactivity can not be induced.
=== Science and religion === Dyson was raised in what he described as a "watered-down Church of England Christianity". He was a nondenominational Christian and attended various churches, from Presbyterian to Roman Catholic. Regarding doctrinal or Christological issues, he said, "I am neither a saint nor a theologian. To me, good works are more important than theology." In The God Delusion (2006), evolutionary biologist and atheist activist Richard Dawkins singled out Dyson for accepting the Templeton Prize in 2000: "It would be taken as an endorsement of religion by one of the world's most distinguished physicists." In 2000, Dyson declared that he was a (non-denominational) Christian, and he disagreed with Dawkins on several subjects, such as that group selection is less important than individual selection in evolution. Dyson partially disagreed with the remark by his fellow physicist Steven Weinberg that "With or without religion, good people can behave well and bad people can do evil; but for good people to do evil – that takes religion."
The defence submitted that there was no case to answer on the air‑embolism allegations, arguing that the prosecution's experts lacked sufficient clinical experience, that the research basis for air embolism was inconsistent, and that expert descriptions of the condition varied. Goss ruled that there was "a sufficient body of accepted medical opinion" to allow the allegation to be considered by the jury.
This is a list of investigational hair loss drugs, or drugs that are currently under development for clinical use in the treatment of different forms of alopecia (hair loss), such as androgenetic alopecia (pattern hair loss) and alopecia areata (spot baldness), but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Route – Indication – Mechanism of Action [Reference]". This list was last comprehensively updated in July 2025. It is likely to become outdated with time.
Sources: en.wikipedia.org
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.
It binds the same ghrelin receptor but with greater selectivity in functional assays. Preclinical work reports less cortisol and prolactin stimulation at growth-hormone-releasing doses. Those differences are relative, not absolute, and depend on dose and model.
No major regulatory authority has approved it for human therapeutic use. It is sold as a research chemical for laboratory investigation. Clinical status varies by country and is subject to change.
It is a synthetic pentapeptide belonging to the growth hormone secretagogue family. Its principal characterized target is the ghrelin receptor, also called GHS-R1a. The molecule contains non-natural amino acids and an amidated C-terminus.